ARTIDIS
ARTIDIS AG is a spinoff from the Biozentrum, University of Basel, Switzerland, that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. ARTIDIS nanotechnology platform integrates different types of clinical data into the ARTIDISNet digital platform, allowing physicians to significantly shorten the current diagnostic process and bringing benefit to both the patient and the healthcare system. ARTIDIS enables professionals to design personalized cancer treatment plans tailored to the individual patient needs and desired outcomes.
Last updated on